n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: A randomized trial

Lipids

Volumn 50, Issue 2, 2015, Pages 165-175

  Hedengran, Anne ^a   Szecsi, Pal B ^a   Dyerberg, Jørn ^a   Harris, William S ^a   Stender, Steen ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Docosahexaenoic acids; Eicosapentaenoic acid; Heart rate; Lipoprotein associated phospholipase A2; n 3 Polyunsaturated fatty acid; Non fasting; Omega 3 acylglycerol; Omega 3 ethyl ester; Triacylglycerols

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DOCOSAHEXAENOIC ACID; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ACYLGLYCEROL; PLACEBO; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACYLGLYCEROL; ESTER;

ADULT; ARTICLE; BLOOD SAMPLING; BONE PAIN; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ECZEMA; EDEMA; EPISTAXIS; ERYTHROCYTE MEMBRANE; ESTERIFICATION; FATIGUE; FEMALE; FEVER; HEART PALPITATION; HEART RATE; HUMAN; HYPERTRIGLYCERIDEMIA; INDIGESTION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; PATIENT COMPLIANCE; PLASMA; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA DISCHARGE; AGED; BLOOD; CHEMISTRY; DIET RESTRICTION; DIET THERAPY; MIDDLE AGED;

AGED; DOUBLE-BLIND METHOD; ESTERS; FASTING; FATTY ACIDS, OMEGA-3; FEMALE; GLYCERIDES; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84922105094     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-014-3968-6     Document Type: Article

References (52)

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829-1839
2. World Health Organization (2009) Global health risks: mortality and burden of diseases attributable to selected major risks. WHO
3. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450-458
4. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, Davis CE (1993) Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328:1220-1225
5. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S (1993) Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 307:1318-1322
6. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308
7. Thomsen M, Varbo A, Tybjaerg-Hansen A, Nordestgaard BG (2014) Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem 60:737-746
8. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143-3421
9. Opinion of Steering Committee of the Norwegian Scientific Committee for Food Safety (2011) Description of the processes in the value chain and risk assessment of decomposition substances and oxidation products in fish oils 19.10.2011, Norwegian Scientific Committee for Food Safety (VKM) p1-147
10. Dyerberg J, Bang HO, Hjorne N (1975) Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 28:958-966
11. Bang HO, Dyerberg J (1972) Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 192:85-94
12. Bang HO, Dyerberg J, Hjoorne N (1976) The composition of food consumed by Greenland Eskimos. Acta Med Scand 200:69-73
13. Harris WS (1989) Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 30:785-807
14. Jacobsen TA (2008) Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 87:1981-1990
15. Kris-Etherton PM, Harris WS, Appel LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757
16. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71:1085-1094
17. Schmidt EB, Kristensen SD, De CR, Illingworth DR (1993) The effects of n-3 fatty acids on plasma lipids and lipoproteins and other cardiovascular risk factors in patients with hyperlipidemia. Atherosclerosis 103:107-121
18. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ (2002) Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20:1493-1499
19. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112:1945-1952
20. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308:1024-1033
21. Schuchardt JP, Hahn A (2013) Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 89:1-8
22. Harris WS (2008) The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr 87:1997S-2002S
23. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189:19-30
24. Harris WS, Connor WE, Alam N, Illingworth DR (1988) Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res 29:1451-1460
25. Schmidt EB, Varming K, Svaneborg N, Dyerberg J (1992) n-3 polyunsaturated fatty acid supplementation (Pikasol) in men with moderate and severe hypertriglyceridaemia: a dose-response study. Ann Nutr Metab 36:283-287
26. Reis GJ, Silverman DI, Boucher TM, Sipperly ME, Horowitz GL, Sacks FM, Pasternak RC (1990) Effects of two types of fish oil supplements on serum lipids and plasma phospholipid fatty acids in coronary artery disease. Am J Cardiol 66:1171-1175
27. Schuchardt JP, Neubronner J, Kressel G, Merkel M, von Schacky C, Hahn A (2011) Moderate doses of EPA and DHA from reesterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids 85:381-386
28. Woodward M, Webster R, Murakami Y, Barzi F, Lam TH, Fang X, Suh I, Batty GD, Huxley R, Rodgers A (2012) The association between resting heart rate, cardiovascular disease and mortality: evidence from 112,680 men and women in 12 cohorts. Eur J Prev, Cardiol
29. Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM (2010) Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 159:612-619
30. Geelen A, Brouwer IA, Schouten EG, Maan AC, Katan MB, Zock PL (2005) Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr 81:416-420
31. Thompson A, Gao P, Orfei L, Watson S, Di AE, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J (2010) Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375:1536-1544
32. Gajos G, Zalewski J, Mostowik M, Konduracka E, Nessler J, Undas A (2014) Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina. Nutr Metab Cardiovasc Dis 24:434-439
33. Pedersen MW, Koenig W, Christensen JH, Schmidt EB (2009) The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 48:1-5
34. Nelson TL, Hokanson JE, Hickey MS (2011) Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr 50:185-193
35. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952
36. Walldius G, Jungner I (2004) Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255:188-205
37. Mensink RP, Zock PL, Kester AD, Katan MB (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77:1146-1155
38. Dangardt F, Osika W, Chen Y, Nilsson U, Gan LM, Gronowitz E, Strandvik B, Friberg P (2010) Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis 212:580-585
39. Dyerberg J, Bang HO (1979) Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 2:433-435
40. Wachira JK, Larson MK, Harris WS (2014) n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr 111:1652-1662
41. Dyerberg J, Madsen P, Moller JM, Aardestrup I, Schmidt EB (2010) Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids 83:137-141
42. Neubronner J, Schuchardt JP, Kressel G, Merkel M, von Schacky C, Hahn A (2011) Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur J Clin Nutr 65:247-254
43. Laidlaw M, Cockerline CA, Rowe WJ (2014) A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. Lipids Health Dis 13:99
44. Krokan HE, Bjerve KS, Mork E (1993) The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim Biophys Acta 1168:59-67
45. Yang LY, Kuksis A, Myher JJ (1990) Lipolysis of menhaden oil triacylglycerols and the corresponding fatty acid alkyl esters by pancreatic lipase in vitro: a reexamination. J Lipid Res 31:137-147
46. Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, Davidson M (2013) Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag 9:563-573
47. Armand M (2007) Lipases and lipolysis in the human digestive tract: where do we stand? Curr Opin Clin Nutr Metab Care 10:156-164
48. Carlier H, Bernard A, Caselli C (1991) Digestion and absorption of polyunsaturated fatty acids. Reprod Nutr Dev 31:475-500
49. Schuchardt JP, Neubronner J, Block RC, von Schacky C, Hahn A (2014) Associations between Omega-3 index increase and triacylglyceride decrease in subjects with hypertriglyceridemia in response to six month of EPA and DHA supplementation. Prostaglandins Leukot Essent Fatty Acids 91:129-134
50. Metcalf RG, James MJ, Gibson RA, Edwards JR, Stubberfield J, Stuklis R, Roberts-Thomson K, Young GD, Cleland LG (2007) Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 85:1222-1228
51. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M (1997) Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 38:2012-2022
52. Meyer BJ, Hammervold T, Rustan AC, Howe PR (2007) Dosedependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids 42:109-115